| Literature DB >> 34290502 |
Joanne Sloots1, Mirthe Bakker1, Job van der Palen1,2, Michiel Eijsvogel1, Paul van der Valk1, Gerard Linssen3, Clara van Ommeren1, Martijn Grinovero4, Monique Tabak5,6, Tanja Effing7, Anke Lenferink1,8.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) often coexist and share periods of symptom deterioration. Electronic health (eHealth) might play an important role in adherence to interventions for the self-management of COPD and CHF symptoms by facilitating and supporting home-based care.Entities:
Keywords: chronic conditions; disease management; dry powder inhalers; self-treatment; telemedicine
Year: 2021 PMID: 34290502 PMCID: PMC8289298 DOI: 10.2147/COPD.S299598
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Content of Self-Management Training Sessions
Self-management information regarding COPD and CHF (e.g. medication, risk factors) Information regarding symptom monitoring, recognition of symptom deterioration and self-treatment of symptoms (e.g. triggers of exacerbations) Introduction and demonstration on how to use the self-management application on a tablet Demonstration how to use the digital weighing scale and Fitbit | |
Discussion of experiences and addressing perceived problems with the eHealth self-management application, digital weighing scale and Fitbit Completion of ‘what are my “usual” symptoms’ card Training on symptom monitoring, recognition of symptom deterioration, and self-treatment of symptoms Practicing completing the daily symptom diary and following up advised actions on the self-management application Practicing the use of the other modules of the self-management application (for more details see paragraph ‘eHealth self-management application modules’) Training inhalation technique of inhaled medication | |
Re-iteration of the use of the self-management application and addressing potential perceived problems Promoting healthy lifestyle behaviors: diet, physical fitness and exercise, quit smoking Practicing breathing- and relaxation exercises Instruction about add-on sensor for inhaled medication (Respiro® by Amiko) for measuring inhaled medication adherence and technique | |
Verifying whether the different modules of the self-management application were used (for more details see paragraph ‘eHealth self-management application modules’) Verifying problems with the use of the self-management application Feedback on diary completion and advised actions |
Content of the eHealth Self-Management Intervention Modules
| Self-management | Phone number of case manager (during office hours) and General Practitioner (outside office hours) Daily symptom diary Automated decision support system that launched a patient’s tailored advised action in case of symptom deterioration. To-do list (e.g. complete diary, initiate self-treatment) Overview: health status (stable, slight or significant deterioration of symptoms), weight (current and difference with the day before), last action that was launched, inhaled medication adherence |
| Monitoring | Detailed overview of health status, self-reported symptoms, advised and performed actions and weight graph |
| Inhalera | Graph illustrating performed inhalations per day and whether the inhalation technique was correctly/incorrectly performed, measured by add-on inhaler sensor (Respiro®) |
| Information | Individualized overview of ‘what are my “usual” symptoms’ General information about COPD, CHF, anxiety, depression, ischemic heart disease, nutrition, physical exercise Link to instruction videos about inhalation technique for all inhaler devices Individualized written action plan on which the automated decision support system was based Copy of patient’s informed consent form |
| Exercise and physical activity | Instruction videos with exercises specified for patients with CHF and COPD: relaxation exercises, exercises to maintain fit, breathing exercises during deterioration of symptoms Graph with number of steps taken per day, measured by a Fitbit® Videos with general information about COPD |
| Embodied Conversational Agent | An Embodied Conversational agent (ECA) - defined as a more or less autonomous and intelligent software entity with an embodiment to communicate with the user |
Notes: aOnly for patients using an add-on inhaler sensor (Respiro®).
Figure 1Flowchart of patient enrollment.
Figure 2Frequency of inhalation error types. Definition of inhalation errors: Too short: flow <1.25s, Too weak: Peak inspiratory Flow (PIF) <30L/min, Orientation error: Orientation of the inhalator <45° or >135°, No closure: Cap of the inhaler was not closed properly.
Baseline Characteristics of Participants Who Completed Follow-Up
| A. General baseline characteristics (n=11) | ||
| 66.8 ± 2.9 | ||
| 7 (63.6) | ||
| 8 (72.2) | ||
| 6 (54.5) | ||
| 27.5 ± 5.5 | ||
| Secondary Education | 2 (18.2) | |
| Trade School | 6 (54.5) | |
| Higher Professional education | 1 (9.1) | |
| Pre-university education | 1 (9.1) | |
| University | 1 (9.1) | |
| B. Baseline Characteristics regarding COPD (n=11) | ||
| 51 (43–59) | ||
| 2A | 1 (9.1) | |
| 2B | 3 (27.3) | |
| 2C | 2 (18.2) | |
| 3A | 1 (9.1) | |
| 3B | 1 (9.1) | |
| 3D | 3 (27.3) | |
| 1 | 4 (36.4) | |
| 2 | 4 (36.4) | |
| 3 | 2 (18.2) | |
| 4 | 1 (9.1) | |
| 0 | 3 (27.3) | |
| 1 | 3 (27.3) | |
| 2 | 2 (18.2) | |
| 3 | 3 (27.3) | |
| 0 | 10 (90.9) | |
| 3 | 1 (9.1) | |
| C. Baseline characteristics regarding CHF and comorbidities (n=11) | ||
| Preserved LVEF | 2 (18.2) | |
| Midrange LVEF | 5 (45.5) | |
| Reduced LVEF | 3 (27.3) | |
| 0 | 5 (45.5) | |
| 1 | 4 (36.4) | |
| 2 | 1 (9.1) | |
| 3 | 1 (9.1) | |
| 0 | 8 (72.7) | |
| 1 | 2 (18.2) | |
| 3 | 1 (9.1) | |
| 2 (18.2) | ||
| 3 (27.3) | ||
| 0–7 (no anxiety disorder) | 8 (72.7) | |
| 8–10 (possible anxiety disorder) | 3 (27.3) | |
| 0–7 (no depressive disorder) | 10 (90.9) | |
| 8–10 (possible depression disorder) | 1 (9.1) | |
Notes: aeHEALS, Range of total scores: 8 (low eHealth literacy) to 40 (high eHealth literacy). bAccording to GOLD guidelines 2021.7 cNumber of courses of prednisolone/antibiotics for deterioration of COPD symptoms one year prior to participation according to patient questionnaire data. dNumber of hospitalizations for COPD according to electronic health record data. ePreserved LVEF: LVEF ≥50%, Midrange LVEF: 40–49%, reduced LVEF <40%.3 Data is missing for one patient because of inconclusive results of the echocardiogram. fNumber of increased diuretics doses for deterioration of CHF symptoms one year prior to participation, according to patient questionnaire data. gNumber of hospitalizations for CHF according to electronic health record data.
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; eHEALS, eHealth Literacy Scale; FEV1%, percentage of predicted Forced Expiratory Volume in 1 second; GOLD, Global Initiative For Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; IQR, interquartile range; CHF, Chronic Heart Failure; LVEF, Left Ventricular Ejection Fraction; HADS, Hospital Anxiety and Depression Scale; IQR, interquartile range.
Adherence to Daily Symptom Diary per Month and in Total
| Number of Diary Days | Diary Completion the Actual Day, n (%) | Diary Completion Next Day or Later, n (%) | Diary Not Completed, n (%) | |
|---|---|---|---|---|
| Month 1 (October) | 242 | 225 (93.0) | 1 (0.4) | 16 (6.6) |
| Month 2 (November) | 330 | 312 (94.5) | 3 (0.9) | 15 (4.5) |
| Month 3 (December) | 339 | 296 (87.3) | 9 (2.7) | 34 (10.0) |
| Month 4 (January) | 334 | 301 (90.1) | 15 (4.5) | 18 (5.4) |
| Month 5 (February) | 16 | 14 (87.5) | 0 | 2 (12.5) |
| 1261 | 1148 (91.0) | 28 (2.2) | 85 (6.7) |
Notes: Adherence was measured starting from the patient’s individual self-management training session (first two weeks of October 2018), till their last completed diary (last week of January/first week of February 2019). 23 diary days were excluded because the system failed. For 119 diary days, diaries were completed twice because of a system failure. Only one set of these double daily entrees was included.
Abbreviations: n, Number of days, (%) percentage of total.
Action Plan Adherence During Follow-Up Time
| Required Action According to Action Plan | Number of Advised Actions | Performed Actions | Unperformed Actions | Reasons Actions Not Performed |
|---|---|---|---|---|
| Initiate prednisolone course | 2 | 1 | 1 | - Treatment started 2 days ago after consult with case manager (n=1) |
| Initiate prednisolone and antibiotic courses | 3 | 1 | 2 | - Hospitalized (n=1) |
| Increase diuretic dose | 3 | 2 | 1 | - Hospitalized (n=1) |
| Have a NT-proBNP Lab-test | 2 | 0 | 2 | - Hospitalized (n=1) |
| Perform relaxation exercises | 1 | 0 | 1 | - Unclear (n=1) |
| Contact case managera | - Phone connection failed (n=1) | |||
| - Dizziness | 10 | 5 | 5 | |
| - Symptoms did not improve | 1 | 1 | 0 | |
| - Symptoms and dizzinessb | 2 | 1 | 1 | |
| Total number of actions | 24 | 11 (46%) | 13 (54%) |
Notes: Patients were advised to call the case manager in case they reported dizziness and/or symptoms did not improve after two days of self-treatment. bReported dizziness and symptoms did not improve after two days of self-treatment.
Abbreviation: %, percentage of total number of actions.
Inhaled Medication Adherence and Technique per Patient During Follow-Up
| 1* | 107 (100) | 76 (71.0) | 14 – 100 |
| 2* | 116 (100) | 25 (21.6) | 0 – 57 |
| 3* | 111 (98.2) | 69 (62.2) | 14 – 100 |
| 4 | 105 (96.3) | 50 (47.6) | 0 – 71 |
| 5* | 110 (97.3) | 76 (69.1) | 14 – 100 |
| 6 | 112 (97.4) | 19 (17.0) | 0 – 57 |
| 7 | 91 (100) | 75 (82.4) | 71– 100 |
Notes: *Switched to inhaler device Ellipta® at the start of the study. aMissing data on inhalations because of low battery: patient 4: 5 inhalations, patient 7: 27 inhalations. bA correct inhalation is defined as flow >1.25 s, Peak Inspiratory Flow >30 L/min, Orientation between 45° and 135°. cMissings because inhalation not performed or low battery: patient 3: 2, patient 4: 9, patient 5: 3, patient 6: 3, patient 7: 27.
Quality of Life at Baseline and After Follow-Up
| Questionnaire | Baseline | Follow-Up (4 Months) |
|---|---|---|
| COPD self-efficacy score, mean (SD)a | 75.2 (26.6) | 73.9 (22.8) |
| Partners in Health, mean (SD)b | 81.7 (8.1) | 86.4 (4.0) |
| MLHFQ, median (IQR)c | 37 (3–66) | 34 (0–52) |
| SGRQ, median (IQR)d | 45.0 (9.2–68.2) | 43.1 (6.9–64.0) |
| HADS anxiety, median (IQR)e | 5 (2–10) | 5 (0–12) |
| HADS depression, median (IQR)e | 5 (1–10) | 4 (1–9) |
Notes: Missings: COPD self-efficacy score: 4 patients, MLHFQ: 3 patients. aRange of total scores: 34 (low COPD self-efficacy) to 170 (high COPD self-efficacy). bRange of total scores: 0 (low self-management behavior and knowledge) to 96 (high self-management behavior and knowledge). cRange of total scores: 0 (high heart failure related quality of life) to 105 (low heart failure related quality of life). dRange of total score: 0 (high respiratory related quality of life) to 100 (low respiratory related quality of life). eHADS: Score 0–7= no anxiety/depression disorder, score 8–10= possible anxiety/depression disorder, score 11–21= probable anxiety/depression disorder.
Abbreviations: MLHFQ, Minnesota Living with Heart Failure Questionnaire; SGRQ, St. George Respiratory Questionnaire; HADS, Hospital Anxiety Depression Score.